Johnson & Johnson’s Kenvue consumer health business is preparing for an initial public offering of more than 151 million shares.
The health care giant said late Monday that the per-share IPO price for Kenvue Inc. should range between $20 and $23. J&J said Kenvue has launched a road show for its IPO. That involves the company talking to potential investors ahead of the offering.
The consumer health business sells well-known products like Band-Aids, Listerine and over-the-counter medicines such as Tylenol. J&J has said it expects an IPO by the end of the year.
J&J announced in late 2021 that it was splitting its consumer health division from the pharmaceutical and medical device divisions in a bid to make each more nimble.
-based J&J’s remaining businesses focus on pharmaceuticals and medical devices.
Kenvue has applied to list its stock under the ticker symbol “KVUE” on the New York Stock Exchange.
J&J, New Brunswick, New Jersey, will still own more than 90% of Kenvue’s shares after the IPO.
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
